Apple has won a preliminary decision at a U.S. trade tribunal in its dispute with Masimo over Apple Watch patents tied to blood-oxygen monitoring technology.
A judge at the U.S. International Trade Commission found that Apple’s redesigned watches do not infringe the patents cited by Masimo. The ruling blocks, for now, Masimo’s effort to secure a new import ban on Apple’s current smartwatch models.
The dispute follows a 2023 import ban that forced Apple to change the watch’s blood-oxygen feature. Apple later resumed imports after redesigning the product to avoid infringement concerns.
In a separate development, a federal appeals court upheld the earlier 2023 ruling that had blocked imports of earlier infringing models. Apple said it welcomed the latest tribunal decision and is reviewing further legal options.
The case remains part of a wider patent battle between the two companies, with additional lawsuits still ongoing in U.S. courts.
